Previous 10 | Next 10 |
Annovis Bio to Present at the 2022 ThinkEquity Investor Conference PR Newswire BERWYN, Pa. , Oct. 20, 2022 /PRNewswire/ -- (NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative dise...
Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's Disease PR Newswire BERWYN, Pa. , Oct. 11, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical dru...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Robert Way / Shutterstock.com Fans of Polestar Automotive (NASDAQ: PSNY ) stock will want to keep an eye on the company as a potential catalyst is coming on Oct. 12 . This coming up Wednesday, Polesta...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: pathdoc / Shutterstock.com Annovis Bio (NYSE: ANVS ) stock is getting a boost on Thursday following news that the company will proceed with its Alzheimer’s Disease clinical trial . FDA has sign...
Annovis Bio ( NYSE: ANVS ) said it received authorization from the U.S. Food and Drug Administration (FDA) to start a phase 2/3 trial of buntanetap to treat moderate Alzheimer's Disease (AD). After filing phase 2a safety data and chronic toxicology data ...
Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer's Disease PR Newswire BERWYN, Pa. , Oct. 6, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug p...
Summary Green light received from the FDA to initiate a phase 3 study using buntanetap for the treatment of early-stage Parkinson's Disease patients. The global Parkinson's Disease market is expected to reach $8.38 billion by end of 2026. Potential to receive clearance to init...
Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference PR Newswire BERWYN, Pa. , Sept. 29, 2022 /PRNewswire/ -- (NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative...
Drug platform company Annovis Bio, Inc. ( NYSE: ANVS ) announced Tuesday the publication of three granted U.S. patents covering lead product candidate buntanetap. The patents relate to methods of treating amyloid lateral sclerosis (ALS), Huntington's disease, and prion dis...
Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases PR Newswire BERWYN, Pa. , Sept. 13, 2022 /PRNewswire/ -- (NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a cli...
News, Short Squeeze, Breakout and More Instantly...
Annovis Bio (NYSE: ANVS) , a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced the receipt of U.S. Patent No. 12,042,482. The patent ...
MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’...
The new executive team includes Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen These additions are pivotal as the company makes strides toward bringing flagship drug candidate buntanetap closer to New Drug Application (“NDA”) status and to market Annovis Bio (NYS...